Lamia Y Haque1, Jenna L Butner, Julia M Shi, Susan Henry, Yanhong Deng, Maria M Ciarleglio, Lynn M Madden, Jeanette M Tetrault. 1. From the Yale School of Medicine, Department of Internal Medicine, Section of Digestive Diseases, New Haven, CT (LYH); Yale School of Medicine, Department of Internal Medicine, Section of General Internal Medicine, New Haven, CT (JLB); APT Foundation and Yale School of Medicine, Department of Internal Medicine, Section of General Internal Medicine, New Haven, CT (JMS); APT Foundation, New Haven, CT (SH); Yale School of Medicine, Yale Liver Center and Yale Center for Analytical Sciences, New Haven, CT (YD); Yale School of Public Health, Department of Biostatistics, New Haven, CT (MMC); APT Foundation and Yale School of Medicine, New Haven, CT (LMM); Yale School of Medicine, Department of Internal Medicine, Program in Addiction Medicine, New Haven, CT (JMT).
Abstract
OBJECTIVES: Treatment of hepatitis C virus infection (HCV) with direct acting antiviral therapy is encouraged regardless of substance use status. Patients with substance use disorder are at risk of HCV reinfection after cure. Follow up viral load testing (FUVL) with HCV RNA is recommended. We investigated factors associated with adoption of FUVL in real-world clinical settings. METHODS: Medical records of all patients with SUD who achieved HCV cure with direct acting antivirals at a multidisciplinary addiction treatment program between 2014 and 2019 were reviewed as part of a quality improvement initiative. Demographic and clinical characteristics including SUD treatment, urine toxicology results, and medical service use were collected. Factors associated with FUVL were analyzed and the rate of HCV reinfection was determined. RESULTS: Among 149 patients, 58.4% received FUVL. Receipt of FUVL was associated with engagement in ongoing primary medical care after cure (AOR 4.39, 95% CI [1.67, 11.49]). The HCV reinfection rate among those who received FUVL was 1.95 per 100 person-years of follow up (95% CI [0.64, 5.98]). There was no significant difference in the percentage of negative urine toxicology results before and after cure. CONCLUSIONS: Over half of a cohort of patients with substance use disorder cured of HCV received FUVL. The relationship between FUVL and engagement in primary medical and substance use treatment highlights the importance of integrated systems in providing longitudinal care for patients cured of HCV. Standardized interventions that facilitate FUVL testing and management of infectious complications of SUD in addiction treatment settings are needed.
OBJECTIVES: Treatment of hepatitis C virus infection (HCV) with direct acting antiviral therapy is encouraged regardless of substance use status. Patients with substance use disorder are at risk of HCV reinfection after cure. Follow up viral load testing (FUVL) with HCV RNA is recommended. We investigated factors associated with adoption of FUVL in real-world clinical settings. METHODS: Medical records of all patients with SUD who achieved HCV cure with direct acting antivirals at a multidisciplinary addiction treatment program between 2014 and 2019 were reviewed as part of a quality improvement initiative. Demographic and clinical characteristics including SUD treatment, urine toxicology results, and medical service use were collected. Factors associated with FUVL were analyzed and the rate of HCV reinfection was determined. RESULTS: Among 149 patients, 58.4% received FUVL. Receipt of FUVL was associated with engagement in ongoing primary medical care after cure (AOR 4.39, 95% CI [1.67, 11.49]). The HCV reinfection rate among those who received FUVL was 1.95 per 100 person-years of follow up (95% CI [0.64, 5.98]). There was no significant difference in the percentage of negative urine toxicology results before and after cure. CONCLUSIONS: Over half of a cohort of patients with substance use disorder cured of HCV received FUVL. The relationship between FUVL and engagement in primary medical and substance use treatment highlights the importance of integrated systems in providing longitudinal care for patients cured of HCV. Standardized interventions that facilitate FUVL testing and management of infectious complications of SUD in addiction treatment settings are needed.
Authors: Evan B Cunningham; Behzad Hajarizadeh; Janaki Amin; Margaret Hellard; Julie Bruneau; Jordan J Feld; Curtis Cooper; Jeff Powis; Alain H Litwin; Philippa Marks; Olav Dalgard; Brian Conway; Alberto Moriggia; Catherine Stedman; Phillip Read; Philip Bruggmann; Karine Lacombe; Adrian Dunlop; Tanya L Applegate; Gail V Matthews; Chris Fraser; Gregory J Dore; Jason Grebely Journal: Clin Infect Dis Date: 2021-04-26 Impact factor: 9.079
Authors: Jasmine Schulkind; Brian Stephens; Farsana Ahmad; Linda Johnston; Sharon Hutchinson; Donna Thain; Zoe Ward; Peter Vickerman; Matt Hickman; John F Dillon Journal: J Viral Hepat Date: 2018-12-12 Impact factor: 3.728
Authors: Jeffrey E Korte; Kathryn M Magruder; Codruta C Chiuzan; Sarah L Logan; Therese Killeen; Dipankar Bandyopadhyay; Kathleen T Brady Journal: Am J Drug Alcohol Abuse Date: 2011-09 Impact factor: 3.829
Authors: Carmine Rossi; Zahid A Butt; Stanley Wong; Jane A Buxton; Nazrul Islam; Amanda Yu; Maryam Darvishian; Mark Gilbert; Jason Wong; Nuria Chapinal; Mawuena Binka; Maria Alvarez; Mark W Tyndall; Mel Krajden; Naveed Z Janjua Journal: J Hepatol Date: 2018-08-22 Impact factor: 25.083
Authors: Amanda Weir; Allan McLeod; Hamish Innes; Heather Valerio; Esther J Aspinall; David J Goldberg; Stephen T Barclay; John F Dillon; Ray Fox; Andrew Fraser; Peter C Hayes; Nicholas Kennedy; Peter R Mills; Adrian J Stanley; Celia Aitken; Rory Gunson; Kate Templeton; Alison Hunt; Paul McIntyre; Sharon J Hutchinson Journal: Drug Alcohol Depend Date: 2016-05-28 Impact factor: 4.492